A network pharmacology-based research showed that formononetin might down-regulate ESR1, TP53, and ERBB2 positive expressions and reduce tumor weights in tumor-bearing nude mice hypodermically injected with OS cells [11]. This evidence concerns the gene TP53 and neoplasm.